Departamento de Microbiologia e Parasitologia, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Laboratório Regional de Diagnóstico, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Med Mycol. 2020 Oct 1;58(7):913-918. doi: 10.1093/mmy/myz141.
Pythiosis is a rapidly progressing disease that can be lethal to affected individuals due to resistance to available therapeutic protocols. The disease affects mammals, with the largest number of reports in horses and humans. The present study investigated the activity of biogenic silver nanoparticles (bioAgNP) in the treatment of experimental pythiosis. The disease was reproduced in nine female 90-day-old New Zealand rabbits. Animals were divided into three groups: group1 (control, n = 3) daily and topically treated with a nonionized gel-based formulation and 1 ml of sterile distilled water intralesion administered every 48 hours; group 2 (n = 3), daily and topically treated with gel-based formulation containing 1 μg/ml bio-AgNP; group 3 (n = 3), treated with 1 ml bio-AgNP in 1 μg/ml aqueous solution intralesion administered every 48 hours. Animals were treated for 45 days, and the area of subcutaneous lesions was measured every 5 days. Results showed that groups 2 and 3 differed from control group (P < .05) in the lesion area, as well as the amount of hyphae within the lesions. It was observed that lesions of treated animals (groups 2 and 3) did not differ from each other, showing that the application route did not influence the regression of lesions. However, it was observed that one animal from group 2 reached clinical cure at 35 days of treatment. This research is pioneer in the application of nanocomposites for the treatment of experimental pythiosis and showed that bio-AgNP can be powerful allies of integrative medicine and can be included in pythiosis therapeutic protocols.
棘球蚴病是一种进展迅速的疾病，由于对现有治疗方案的耐药性，受影响的个体可能因此致命。这种疾病影响哺乳动物，其中在马和人中报告的数量最多。本研究调查了生物合成银纳米粒子（bioAgNP）在治疗实验性棘球蚴病中的活性。在 9 只 90 天大的雌性新西兰兔中重现了这种疾病。动物分为三组：第 1 组（对照组，n=3）每天和局部用非离子凝胶制剂和 1ml 无菌蒸馏水治疗，每 48 小时皮损内给药一次；第 2 组（n=3）每天和局部用含 1μg/ml bioAgNP 的凝胶制剂治疗；第 3 组（n=3），用 1ml 含 1μg/ml bioAgNP 的水溶液皮损内每 48 小时给药一次。动物治疗 45 天，每 5 天测量一次皮下病变面积。结果显示，第 2 组和第 3 组与对照组（P<0.05）在病变面积以及病变内菌丝数量上均有差异。观察到治疗动物（第 2 组和第 3 组）的病变没有差异，表明给药途径不会影响病变的消退。然而，观察到第 2 组中的一只动物在治疗 35 天时达到临床治愈。这项研究是在实验性棘球蚴病中应用纳米复合材料的先驱，表明 bioAgNP 可以成为综合医学的有力盟友，并可以纳入棘球蚴病治疗方案。
